Suppr超能文献

年轻前庭神经鞘瘤患者的伽玛刀放射外科治疗

Gamma knife radiosurgery in younger patients with vestibular schwannomas.

作者信息

Lobato-Polo Javier, Kondziolka Douglas, Zorro Oscar, Kano Hideyuki, Flickinger John C, Lunsford L Dade

机构信息

Department of Neurological Surgery and the Center for Image-Guided Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.

出版信息

Neurosurgery. 2009 Aug;65(2):294-300; discussion 300-1. doi: 10.1227/01.NEU.0000345944.14065.35.

Abstract

OBJECTIVE

Management options for patients with vestibular schwannoma include observation, surgical resection, stereotactic radiosurgery (SRS), and stereotactic radiation therapy. In younger patients, resection is often advocated because of concern regarding the long-term effects of radiation. We studied tumor response and clinical outcomes after SRS in such patients.

METHODS

We reviewed long-term outcomes in 55 patients with vestibular schwannomas. Patients were 40 years of age or younger, underwent gamma knife (GK) SRS between 1987 and 2003, and were followed up for a minimum of 4 years. The median patient age was 35 years (range, 13-40 years). Forty-one patients had Gardner-Robertson class 1 to 4 hearing. Thirteen patients (24%) had undergone surgical removal. The median tumor volume was 1.7 mm. The median tumor margin dose was 13.0 Gy (range, 11-20 Gy).

RESULTS

At a median of 5.3 years, (range, 4-20 years), 2 of 55 patients underwent GK SRS for a second time; 1 of these patients had had a recurrence after initial resection. The 5-year rate of freedom from additional management was 96%. Hearing preservation rates (i.e., remaining within the same Gardner-Robertson hearing class) were 93%, 87%, and 87% at 3, 5, and 10 years, respectively. In patients with serviceable hearing before SRS, it was maintained in 100%, 93%, and 93% of patients at 3, 5, and 10 years, respectively. Hearing preservation was related to a margin dose lower than 13 Gy (P = 0.017). At the last assessment, facial and trigeminal nerve function was preserved in 98.2% and 96.4% of patients, respectively; the only facial deficit (House-Brackmann grade III) occurred in a patient who received a tumor dose of 20 Gy early in our experience (1988). None of the patients treated with doses lower than 13 Gy experienced facial or trigeminal neuropathy. All patients continued their previous level of activity or employment after GK SRS. No patient developed a secondary radiation-related tumor.

CONCLUSION

Our experience indicates that GK SRS is an effective management strategy for younger patients with vestibular schwannoma, most of whom have no additional cranial nerve dysfunction.

摘要

目的

前庭神经鞘瘤患者的治疗选择包括观察、手术切除、立体定向放射外科治疗(SRS)和立体定向放射治疗。对于年轻患者,由于担心放疗的长期影响,通常主张进行手术切除。我们研究了此类患者接受SRS后的肿瘤反应和临床结果。

方法

我们回顾了55例前庭神经鞘瘤患者的长期结果。患者年龄在40岁及以下,于1987年至2003年接受伽玛刀(GK)SRS治疗,并至少随访4年。患者中位年龄为35岁(范围13 - 40岁)。41例患者的听力分级为Gardner - Robertson 1至4级。13例患者(24%)曾接受过手术切除。肿瘤中位体积为1.7立方毫米。肿瘤边缘中位剂量为13.0 Gy(范围11 - 20 Gy)。

结果

中位随访5.3年(范围4 - 20年),55例患者中有2例接受了第二次GK SRS治疗;其中1例患者在初次切除后复发。无需进一步治疗的5年生存率为96%。听力保留率(即保持在相同的Gardner - Robertson听力分级)在3年、5年和10年时分别为93%、87%和87%。在SRS前听力尚可的患者中,分别有100%、93%和93%的患者在3年、5年和10年时听力得以保留。听力保留与边缘剂量低于13 Gy相关(P = 0.017)。在最后一次评估时,分别有98.2%和96.4%的患者保留了面神经和三叉神经功能;唯一的面部功能障碍(House - Brackmann III级)发生在我们早期经验中(1988年)接受20 Gy肿瘤剂量的1例患者身上。接受低于13 Gy剂量治疗的患者均未出现面部或三叉神经病变。所有患者在GK SRS后继续从事之前的活动或工作。没有患者发生继发性放射性肿瘤。

结论

我们的经验表明,GK SRS是年轻前庭神经鞘瘤患者的一种有效治疗策略,这些患者大多数没有额外的颅神经功能障碍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验